推荐产品
product name
Camptothecin, 10-Hydroxy-, Camptotheca acuminata, A cell-permeable powerful DNA topoisomerase I inhibitor.
品質等級
化驗
≥95% (HPLC)
形狀
powder
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
顏色
pale yellow
溶解度
DMSO: 5 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
InChI
1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3
InChI 密鑰
HAWSQZCWOQZXHI-UHFFFAOYSA-N
一般說明
A cell-permeable powerful DNA topoisomerase I inhibitor. Reduces DNA synthesis in vitro in murine hepatoma cells. Has selective inhibitory effect on the phosphorylation of histone H1 and H3, but less effect on other histones.
A cell-permeable, powerful DNA topoisomerase I inhibitor. Reduces DNA synthesis in vitro in murine hepatoma cells. Inhibits the proliferation of hepatoma HepG2, Bcl-7402 and Bcl-7404 cells in a dose-dependent manner. Has selective inhibitory effect on the phosphorylation of histones H1 and H3, but is less effective on other histones.
生化／生理作用
Cell permeable: yes
Primary Target
DNA topoisomerase I
DNA topoisomerase I
Product does not compete with ATP.
Reversible: no
警告
Toxicity: Irritant (B)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
其他說明
Zhang, X.W., et al. 1999. Anticancer Drugs.10, 569.
Ling, Y.H., et al. 1993. Anticancer Res. 13, 1613.
Wani, M.C., and Wall, M.E. 1969. J. Org.Chem.34, 1364.
Ling, Y.H., et al. 1993. Anticancer Res. 13, 1613.
Wani, M.C., and Wall, M.E. 1969. J. Org.Chem.34, 1364.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 3 Oral - Muta. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Mengfan Tang et al.
Nucleic acids research, 49(13), 7476-7491 (2021-07-02)
Poly (ADP-ribose) polymerase inhibitor (PARPi)-based therapies initially reduce tumor burden but eventually lead to acquired resistance in cancer patients with BRCA1 or BRCA2 mutation. To understand the potential PARPi resistance mechanisms, we performed whole-genome CRISPR screens to discover genetic alterations
Venugopal R Bovilla et al.
Biomedicines, 9(9) (2021-09-29)
Nuclear factor erythroid-2 related factor-2 (Nrf2) is an oxidative stress-response transcriptional activator that promotes carcinogenesis through metabolic reprogramming, tumor promoting inflammation, and therapeutic resistance. However, the extension of Nrf2 expression and its involvement in regulation of breast cancer (BC) responses
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门